Expert advice on anti-novel coronavirus vaccination for tuberculosis patients

doi:10.3969/j.issn.1000-6621.2021.12.003

Abstract

Abstract:

The epidemic of Corona Virus Disease 2019 (COVID-19) is still widespread in the world. As an important measure to control the epidemic, the COVID-19 vaccine is being promoted worldwide. Tuberculosis (TB) patients are high risk group to be infected by COVID-19 and suffer severe, therefore, priority vaccinate should be given to them. However, at present, there is not enough evidence of high quality evidence-based medicine for whether TB patients could be vaccinated and how to vaccinated COVID-19 vaccine. Based on WHO recommendations and related technical guidelines in China, as well as combined with the actual situation of TB patients, the Tuberculosis Branch of Chinese Medical Association, put forward the expert advice on vaccination for this special group. It is recommended that all TB patients should be vaccinated except for active TB patients in the course of anti-tuberculosis reinforcement or combined with other unstable chronic diseases.

Key words: Tuberculosis, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Vaccine, Vaccinate

Tuberculosis Branch of Chinese Medical Association . Expert advice on anti-novel coronavirus vaccination for tuberculosis patients[J]. Chinese Journal of Antituberculosis, 2021, 43(12): 1239-1242. doi: 10.3969/j.issn.1000-6621.2021.12.003

References 19

[1]	中华人民共和国国家卫生健康委员会. 新冠病毒疫苗接种技术指南(第一版). 中华临床感染病杂志, 2021, 14(2):89-90. doi: 10.3760/cma.j.issn.1674-2397.2021.02.002. doi: 10.3760/cma.j.issn.1674-2397.2021.02.002
[2]	中华医学会感染病学分会艾滋病丙型肝炎学组. 成人人类免疫缺陷病毒感染者新型冠状病毒疫苗接种专家建议. 中华内科杂志, 2021, 60(7):615-618. doi: 10.3760/cma.j.cn112138.20210403-00259. doi: 10.3760/cma.j.cn112138.20210403-00259
[3]	中华医学会感染病学分会, 中华医学会风湿病学分会. 特殊人群(慢性肝病、结核病和风湿免疫病患者)新型冠状病毒疫苗接种专家建议. 中华传染病杂志, 2021, 39(7):398-403. doi: 10.3760/cma.j.cn311365-20210507-00163. doi: 10.3760/cma.j.cn311365-20210507-00163
[4]	World Health Organization. Global Tuberculosis Report 2021. Geneva: World Health Organization, 2021.
[5]	Fei H, Yinyin X, Hui C, et al. The impact of the COVID-19 epidemic on tuberculosis control in China. Lancet Reg Health West Pac, 2020, 3:100032. doi: 10.1016/j.lanwpc.2020.100032. doi: 10.1016/j.lanwpc.2020.100032
[6]	Cilloni L, Fu H, Vesga JF, et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinicalMedicine, 2020, 28:100603. doi: 10.1016/j.eclinm.2020.100603. doi: 10.1016/j.eclinm.2020.100603 URL
[7]	Wu Z, Chen J, Xia Z, et al. Impact of the COVID-19 pandemic on the detection of TB in Shanghai, China. Int J Tuberc Lung Dis, 2020, 24(10):1122-1124. doi: 10.5588/ijtld.20.0539. doi: 10.5588/ijtld.20.0539 URL
[8]	沈鑫, 沙巍, 刘剑君. 新型冠状病毒肺炎疫情对结核病防控的影响及对策. 中国防痨杂志, 2020, 42(6):544-548. doi: 10.3969/j.issn.1000-6621.2020.06.003. doi: 10.3969/j.issn.1000-6621.2020.06.003
[9]	Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviru-ses: is faecal-oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol Hepatol, 2020, 5(4):335-337. doi: 10.1016/S2468-1253(20)30048-0. doi: 10.1016/S2468-1253(20)30048-0 URL
[10]	Wang Y, Wang Y, Chen Y, et al. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol, 2020, 92(6):568-576. doi: 10.1002/jmv.25748. doi: 10.1002/jmv.25748 URL
[11]	Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020, 323(11):1061-1069. doi: 10.1001/jama.2020.1585. doi: 10.1001/jama.2020.1585 URL
[12]	Yang H, Lu S. COVID-19 and Tuberculosis. J Transl Int Med, 2020, 8(2):59-65. doi: 10.2478/jtim-2020-0010. doi: 10.2478/jtim-2020-0010 URL
[13]	Liu Y, Bi L, Chen Y, et al. Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity[J/OL]. medRxiv, 2020[2021-09-27]. doi: 10.1101/2020.03.10.20033795. Online ahead of print. doi: 10.1101/2020.03.10.20033795
[14]	Ranzani OT, Hitchings MDT, Dorion M, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ, 2021, 374:n2015. doi: 10.1136/bmj.n2015. doi: 10.1136/bmj.n2015
[15]	Tanriover MD, Dogˇanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet, 2021, 398(10296):213-222. doi: 10.1016/S0140-6736(21)01429-X. doi: 10.1016/S0140-6736(21)01429-X URL
[16]	Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomi-sed, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis, 2021, 21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. doi: 10.1016/S1473-3099(21)00127-4 URL
[17]	Wu S, Huang J, Zhang Z, et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis, 2021: S1473-3099(21)00396-0. doi: 10.1016/S1473-3099(21)00396-0. doi: 10.1016/S1473-3099(21)00396-0
[18]	Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 2020, 396(10249):479-488. doi: 10.1016/S0140-6736(20)31605-6. doi: 10.1016/S0140-6736(20)31605-6 URL
[19]	Tadolini M, Codecasa LR, García-García JM, et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J, 2020, 56(1):2001398. doi: 10.1183/13993003.01398-2020. doi: 10.1183/13993003.01398-2020 URL